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INTRODUCTION
1.1. Hypertension Epidemiology:
Cardiovascular diseases such as coronary heart disease and stroke are the largest
causes of death in developing countries and are one of the main contributors to disease
burden. Between years 1990 and 2020 these diseases are anticipated to increase by 120%
for women and 137% for men in developing countries. In India about 70% of coronary
heart disease-related deaths occur in people younger than 70 years compared with 22% in
the west and 94% stroke deaths occurs in people less than 70 years in contrast to 6% in
developed countries. Blood pressure (BP) is directly associated with risks of several types
of cardiovascular diseases and the associations of BP with disease risk are continuous with
large proportions of most populations having non-optimal blood pressure values. In India
cardiovascular  diseases  cause  1.5  million  deaths  annually.  Hypertension  is  directly
responsible for 57% of all stroke deaths and 24% of all coronary heart disease deaths. This
fact is important because hypertension is a controllable disease and a 2 mm Hg population
wide decrease in BP can prevent 151,000 stroke and 153,000 coronary heart disease deaths.
Better  control  can lead to prevention of 300,000 of the 1.5 million annual deaths  from
cardiovascular diseases in India.
1.2. Etiology of Hypertension:   
                          Blood pressure is the force with which blood pushes against the artery
walls as it travels through the body. Blood pressure is measured by two numbers—systolic
pressure and diastolic pressure. Systolic pressure measures cardiac output and refers to the
pressure  in  the  arterial  system  at  its  highest.  Diastolic  pressure  measures  peripheral
resistance and refers to arterial pressure at its lowest. Blood pressure is normally measured
at the brachial artery with a sphygmomanometer (pressure cuff) in millimeters of mercury
(mm Hg) and given as systolic over diastolic pressure. The upper number is the systolic
pressure, which is the peak force of blood as the heart pumps it. The lower number is the
diastolic pressure, which is the pressure when the heart is filling or relaxing before the next
beat.  Normal  blood pressure for an adult  is  120/70 (on average)  Hypertension,  or high
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blood pressure,  is defined as a reading of 140/90 on three consecutive measurements at
least six hours apart. Hypertension is a major cause of stroke.
1.3. Types of Hypertension:
There are two major types of hypertension and four less frequently found types.
The two major types are:
1. Primary or essential hypertension
2. Secondary hypertension 
The other types include:
 Malignant Hypertension. 
 Isolated Systolic Hypertension 
 White Coat Hypertension 
 Resistant Hypertension 
1.3.1. Primary or essential hypertension:
Primary hypertension has no specific origin but is strongly associated with lifestyle.
It is responsible for 90 to 95 percent of diagnosed hypertension and is treated with
stress management, changes in  diet, increased physical activity and medication (if
needed).
1.3.2. Secondary hypertension:
Secondary  hypertension  is  responsible  for  5  to  10  percent  of  diagnosed
hypertension. It  is  caused by a preexisting medical  condition such as congestive
heart  failure,  kidney failure,  liver failure,  or damage to the endocrine (hormone)
system.
1.4. Stages of Hypertension:
The  concept  of  “stage  of  hypertension”  was  determined  in  the  U.S.  by  the  Joint
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood
Pressure (JNC7). 
There are three stages of hypertension:
1. Prehypertension
2. Stage 1 Hypertension
3. Stage 2 Hypertension
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Categories for blood pressure levels in adults are given in Table no.1
TABLE: 1 CATEGORIES FOR BLOOD PRESSURE LEVELS IN ADULTS
 Blood Pressure Level (mmHg)
Category Systolic  Diastolic 
Normal < 120 and < 80
Prehypertension 120-139 or 80-89
High Blood Pressure  
Stage 1 Hypertension 140–159 or 90–99
Stage 2 Hypertension 160 or 100
1.5. Treatment of hypertension  (3):
Medications that lower blood pressure are often referred to as antihypertensive drugs.
Generally these drugs are classified by how they work. 
• Diuretics
• Beta-adrenergic blocking agents
• Calcium channel blockers 
• Angiotensin converting enzyme (ACE) inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Vasodilators
1.6. Angiotensin II Receptor Blockers  (ARBs):
The  renin-angiotensin  system,  specifically  angiotensin  II,  is  implicated  in  the
pathogenesis of essential hypertension, renovascular hypertension, congestive heart failure,
and renal diseases associated with albuminuria. Blockade of the rennin-angiotensin system
with ACE inhibitors has provided effective treatment of these conditions; however, some of
the adverse effects of ACE inhibitors appear to be unrelated to angiotensin II blockade. For
example,  cough  and  angioedema  are  due  to  other  effects  of  ACE  inhibition,  such  as
degradation of bradykinins and prostaglandins.
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ARBs are used for controlling high blood pressure, treating heart failure and preventing
kidney failure in  people  with  diabetes  or  high  blood  pressure.  They may also  prevent
diabetes and reduce the risk of stroke in patients with high blood pressure and an enlarged
heart. ARBs may also prevent the recurrence of atrial fibrillation.
1.6.1. ARBs have the following actions:
• Dilate  arteries  and  veins  and  thereby  reduce  arterial  pressure  and  preload and
afterload on the heart. 
• Down  regulate  sympathetic  adrenergic  activity  by  blocking  the  effects  of
angiotensin II on sympathetic nerve release and reuptake of norepinephrine. 
• Promote renal excretion of sodium and water (natriuretic and  diuretic effects) by
blocking the effects of angiotensin II in the kidney and by blocking angiotensin II
stimulation of aldosterone secretion. 
• Inhibit cardiac and vascular remodeling associated with chronic hypertension, heart
failure, and myocardial infarction. 
1.7. General Introduction:
Oral  drug  delivery  is  the  most  desirable  and  preferred  method  of  administering
therapeutic  agents  for  their  systemic  effects.  In  addition,  the  oral  medication  is  generally
considered  as  the  first  avenue investigated  in  the discovery  and  development of  new drug
entities and pharmaceutical formulations, mainly because of patient acceptance, convenience in
administration,  and  cost-effective  manufacturing  process.  For  many  drug  substances,
conventional  immediate-release  formulations  provide  clinically  effective  therapy  while
maintaining the required balance of pharmacokinetic and pharmacodynamic profiles with an
acceptable level of safety to the patient.
1.8. Current technologies in oral drug delivery:
Over the last 3 decades, many novel oral drug therapeutic systems have been invented
along with the appreciable development of drug delivery technology. Although these advanced
DDS  are  manufactured  or  fabricated  in  traditional  pharmaceutical  formulations,  such  as
Tablets,  Capsules,  Sachets,  Suspensions,  Emulsions, and  Solutions, they are superior to the
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conventional  oral  dosage  forms  in  terms  of  their  therapeutic  efficacies,  toxicities,  and
stabilities. 
Based on the desired therapeutic objectives, oral DDS may be assorted into three categories: 
• Immediate-release preparations, 
• Controlled-release preparations and
• Targeted- release preparations. 
1.8.1. Immediate-Release Preparations:
These preparations are primarily intended to achieve faster onset of action for drugs
such  as  analgesics,  antipyretics,  and  coronary  vasodilators.  Other  advantages  include
enhanced  oral  bioavailability  through  transmucosal  delivery  and  pregastric  absorption,
convenience  in  drug  administration  to  dysphasic  patients,  especially  the  elderly  and
bedridden, and new business opportunities.
Conventional  IR  formulations  include  fast  disintegrating  tablets  and  granules  that  use
effervescent mixtures, such as sodium carbonate (or sodium bicarbonate) and citric acid (or
tartaric  acid),  and  superdisintegrants,  such  as  sodium starch  glycolate,  crosscarmellose
sodium, and crospovidone. Current  technologies in fast-dispersing dosage forms include
modified tableting systems, floss or Shear form technology, which employs application of
centrifugal force and controlled temperature, and freeze-drying. 
1.8.2. Controlled-Release Preparations:
The  currently  employed  CR  technologies  for  oral  drug  delivery  are  diffusion-
controlled  systems;  solvent  activated  systems,  and  chemically  controlled  systems.
Diffusion-controlled systems include monolithic and reservoir devices in which diffusion of
the drug is the rate-limiting step, respectively,  through a polymer matrix or a polymeric
membrane. Solvent-activated systems may be either osmotically controlled or controlled by
polymer swelling. Chemically controlled systems release drugs via polymeric degradation
(surface or bulk matrix erosion)  or cleavage  of drug from a polymer chain.  It  is  worth
mentioning here that  the so-called programmed-release (‘‘tailored-release’’)  profile  of  a
final CR product is rarely the outcome of a single pharmaceutical principle. Depending on
the specific  physicochemical  properties  of  the drug in question and desired therapeutic
objectives, different formulation and CR principles may be proportionally combined within
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the  same  dosage  form.  This  task  appears  to  be  simpler  when  realized  in  terms  of
appropriate selection of polymers and excipients that incorporate desired principles.
1.8.3.Targeted-Release Preparations:
Site-specific oral drug delivery requires spatial placement of a drug delivery device
at a desired site within the GI tract. Although it is virtually possible to localize a device
within each part of GI tract, the attainment of site-specific delivery in the oral cavity and
the rectum is relatively easier than in the stomach and the small and large intestines. The
latter requires consideration of both longitudinal and transverse aspects of GI constraints.
Some of the potential CR and site-specific DDSs will be described.
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1. LITERATURE  REVIEW:
Akira et  al.,(1) reported  that  candesartan  cilexetil,8  mg/day,  significantly  reduced  the
progression of CHF when compared with placebo. This 6-month study examined the safety and
efficacy of candesartan cilexetil,  8 mg once daily,  to prevent the progression of congestive
heart failure (CHF).
Omari et al.,(2) reported that complex formation of candesartan with β- cyclodextrins prepared
by  freeze  drying  method  is  chemically  not  stable  due  to  the  formation  of  amorphous
candesartan and compression enhances the instability of candesartan.  In this study the DSC
thermograms for CAND/β-CyD complexes proved the formation of inclusion complexes with
new solid phase. MM studies indicate the partial penetration of CAND into the β-CyD cavity.
Franks et al.,(3) reported that  candesartan cilexetil effectively reduced BP as demonstrated by
CBPM and ABPM measurements and was well tolerated in this group of hypertensive children.
In this study,  eleven patients (mean age 14.2 y) received a final candesartan cilexetil median
daily  dose  of  8  mg  (0.13  mg/kg,  range  2–16  mg). Study  treatment  resulted  in  significant
reductions in systolic and diastolic BP as measured by CBPM (–7.4%, p = 0.03 and –5.9%, p =
0.01, respectively) and by ABPM (–6.0%, p = 0.03 and –10.8%, p = 0.006, respectively), but
no significant reductions as measured by HBPM. No clinically significant changes in laboratory
measures were observed and patients reported nonspecific mild adverse effects.
Erdmann et al.,(4) reported that candesartan cilexetil is safe when compared with placebo in the
treatment  of  patients  with  CHF.  This  study  involved  a  blinded,  independent  review of  all
adverse event data and was performed to assess all-cause mortality and unexpected deaths, and
hospitalisations for acute deterioration of CHF, chronic progression of CHF, other intercurrent
events,  or  accidental  injury/attempted  suicide.  The  descriptive  analysis  included  crude  and
cumulative  incidence  rates  for  mortality  and  cardiac  and  non-cardiac  morbidity  using  the
Kaplan-Meier  method  and  the  log-rank  test.  The  results  demonstrated  a  clinically  non-
significant trend for all relevant events.
7
Graham et al.,(5) reported that candesartan cilexetil is an effective BP-lowering drug when used
alone or  in  combination  with  amlodipine  or  amlodipine  plus  hydrochlorothiazide in  the
treatment  of  moderate-to-severe  essential  hypertension.  This study evaluated the efficacy of
candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination
with amlodipine or  in combination with amlodipine and hydrochlorothiazide in the treatment of
patients  with  moderate-to-severe  essential  hypertension. The  result  demonstrated  that
candesartan is  an  effective  BP-lowering  drug  when  used  alone or  in  combination  with
amlodipine  or  amlodipine  plus  hydrochlorothiazide and  was  well  tolerated  throughout  the
investigation.
Toblli et al.,(6) reported that candesartan cilexetil provides a significant protective role against
morphologic changes in vessels as well as in cavernous spaces of the erectile tissue, caused by
high  blood  pressure,  in  SHR.  This  present  study  was  performed  to  determine  whether  an
angiotensin  II  receptor  blocker  could  protect  cavernous  tissue  (CT)  from  these  structural
alterations in SHR. Male SHR and Wistar-Kyoto (WKY) rats were studied during 4 months.
Rats were divided into three groups: SHR (n=10), SHR with candesartan cilexetil (n=10) and
WKY rats (n=10). Candesartan cilexetil 7.5 mg/kg/day was administered orally throughout the
study. CT was processed for pathology studies. The amount of (1) cavernous smooth muscle
(CSM), (2) vascular smooth muscle (VSM), (3) collagen type III, and the rat endothelial cell
antibody (RECA-1)/tunica media ratio in cavernous arteries were evaluated.
Baguet et al.,(7) reported that candesartan significantly reduces the incidence of cardiovascular
death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic
heart  failure patients with altered left  ventricular  systolic  function,  when added to standard
therapies or as an alternative to ACE inhibitors when these are poorly tolerated. Furthermore,
the study showed that candesartan can protect against myocardial infarction, atrial fibrillation
and diabetes. Tolerance to candesartan is good, but blood pressure and serum potassium and
creatinine levels must be monitored. 
Baguet  et  al.,(8) reported that  candesartan  and  amlodipine  besylate  treatments  may  alter
identically the natural progression of carotid IMT in hypertensive type 2 diabetic patients. This
study consists of 36 months and investigated the effect of candesartan cilexetil (CC) on the
common carotid intima-media thickness (IMT) vs amlodipine besylate (AML) in patients with
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type 2 diabetes and mild to moderate essential hypertension. No significant differences were
observed between the two groups for change in IMT at M12 (−0.001 vs −0.027 mm/year for
CC and AML respectively, p = 0.425), at M24 (−0.033 vs −0.019 mm per year respectively, p
= 0.442). The augmentation in carotid lumen diameter from baseline was statistically greater in
the AML group at the last visit (p = 0.034). BP variations during the study were similar in the
two groups.
Homma et al.,(9) reported that combination therapy with ARB plus ACEI/amlodipine proves
beneficial than the ARB monotherapy in nondiabetic renal disease. Present study compared the
effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with
that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug
treatment,  the candesartan  monotherapy (n=19)  reduced  BP from 154 3/88
2 mmHg  (P<0.05),  and  a  similar  magnitude  of  BP  reductions  was  observed  with  the
combination therapy with candesartan plus ACEI/amlodipine (from 153 2/95 2/88
2 mmHg, P<0.05, n=39). In  contrast,  the  reduction  in  proteinuria  was  greater  with  the
3% at 12 months, n=39) than with the candesartan monotherapy (-25
3%, n=19) Since the reduction in BP was achieved to the same level, the distinct proteinuria-
sparing action of these therapies is attributed to BP-independent mechanisms, which should
vary depending on the agents used.
Pfister et al.,(10)  reported that HD does not influence the elimination kinetics of candesartan.
The  observed  inter-  and  intraindividual  variability  of  oral  clearance  and  the  pronounced
influence  of  HD-induced  volume  contraction  on  the  haemodynamic  effects  of  candesartan
makes it mandatory to carefully monitor HD patients treated with candesartan cilexetil. It was a
repeated dose study (8 mg candesartan cilexetil once daily) in eight male HD patients over a
treatment period of 5 days with an additional observation period of 3 days. Pharmacokinetic
analysis with nonlinear mixed effects modeling (NONMEM) over the whole treatment period
revealed a dependency of  the volume of distribution on body weight  and of  the metabolic
clearance on age and body weight in the studied population. No significant drug elimination by
HD was observed.
McClellan et al.,(11) reported that candesartan cilexetil is effective and well tolerated when used
once daily (as monotherapy or in combination with other antihypertensive agents) in patients
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with mild, moderate or severe hypertension.  once daily, oral candesartan cilexetil 8 to 32mg
dose-dependently and effectively reduces  blood pressure  in patients  with mild to  moderate
essential hypertension. One study showed candesartan cilexetil 16 mg/day to be more effective
than losartan potassium 50 mg/day. Furthermore, the combination of candesartan cilexetil with
either hydrochlorothiazide or amlodipine resulted in additive antihypertensive effects. Pooled
data indicate that the tolerability profile of the drug is not significantly different from that of
placebo, with headache being the most commonly reported event. Adverse events are not dose
related and are mostly mild to moderate in severity.  Candesartan cilexetil is better tolerated
than enalapril, primarily because of a reduced incidence of cough, and was not associated with
the  hypokalaemia  or  hyperuricaemia  seen  with  hydrochlorothiazide  in  a  study  in  patients
aged 75 years.
See et al.,(12) reported that candesartan cilexetil is an effective antihypertensive agent that can
be used alone or in combination with other antihypertensive drugs. It is generally well tolerated
and  may  be  an  option  for  patients  who  cannot  tolerate  angiotensin-converting-enzyme
inhibitors  because  of  cough.   In  clinical  trials,  candesartan  cilexetil  has  produced  a  dose-
dependent  effect  when  given  in  dosages  of  2-32  mg/day.  Observed  trough-to-peak  blood
pressure ratios support a once-daily dosage regimen. The antihypertensive effect of candesartan
cilexetil 4-16 mg/day was as great as that of enalapril 10-20 mg/day and amlodipine 5 mg/day
and  larger  than  that  of  losartan  potassium  50  mg/day.  Adding  candesartan  cilexetil  to
hydrochlorothiazide 12.5-25 mg/day and amlodipine 5 mg/day led to enhanced blood-pressure
reductions  and was well  tolerated.  It  appears  that  candesartan  can decrease renal  perfusion
without adversely affecting renal blood flow and may mediate a decrease in albuminuria in
hypertensive patients with type 2 diabetes.
Stoukides et al.,(13) reported that Candesartan cilexetil provides an alternative antihypertensive
therapy that  is  well  tolerated  and  effective  in  reducing  blood  pressure  in  a  wide  range  of
patients. Due to its greater binding affinity to the angiotensin II receptor, candesartan cilexetil
appears to have a longer antihypertensive effect than losartan.  In this experiment the Study and
review  articles  describing  the  chemistry,  human  pharmacology,  pharmacodynamics,
pharmacokinetics,  placebo-controlled  trials,  comparative  trials,  and  clinical  application  of
candesartan cilexetil  based on the published literature and premarketing clinical  trials  were
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reviewed. The study showed that Candesartan cilexetil has demonstrated reductions in blood
pressure  comparable  to  those  of  enalapril,  with  the  rate  of  adverse  events  greater  in  the
enalapril group. 
Vijaykumar et al.,(14) reported that the wet bead milling process coupled with spray granulation
is  a  viable  approach  for  developing  nanoparticle  formulations  of  biopharmaceutics
classification system (BCS) class II compounds with enhanced solubility and faster dissolution.
In this study the granules containing drug nanoparticles of KC, FF and CC were blended with
extra-granular excipients using a double cone blender. The blend was subsequently compressed
into tablets at the desired strength, and the physical properties of tablets — hardness, friability
and disintegration time — were measured. Enhancing solubility and dissolution velocity of
sparingly  soluble  compounds  correlates  with  an  improved  pharmacokinetics  profile  and  a
concomitantly improved therapeutic outcome.
Fang Gao et al.,(15) reported that the nanoemulsion was very effective for enhancing the oral
absorption of insoluble CC, and CCN showed the great potential for clinical application. In this
work,  a  novel  CC  loaded  nanoemulsion  (CCN)  was  designed  to  improve  the  intestinal
absorption.  CCN was prepared by a modified emulsification-solvent evaporation technique.
The physicochemical characteristics of CCN were characterized, and the intestinal absorption
was investigated as well. The experimental  results indicated that CCN was nanometer-sized
droplets  (35.5 ± 5.9 nm)  with  negative  potential  (− 6.45 ± 0.36 mV),  and  the  absorption  of
CCN was significantly improved in total intestinal tract compared with free CC solution. The
experimental  results  showed that  the area under the concentration–time curve (AUC0–t) of
candesartan was improved over 10-fold after CC was incorporated into CCN.
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1.1. DRUG PROFILE:
Physiochemical nature of the Candesartan cilexetil is given in Table no. 2.
TABLE: 2 PHYSIOCHEMICAL NATURE OF CANDESARTAN 
S.No Physiochemical Nature Description
1 Common Name Candesartan cilexetil
2 Nature Prodrug
3 State Solid
4 Colour White to off white
5 Taste Sour to bitter
6 IUPAC Name
2-ethoxy-3-[[4-[2-(2H-tetrazol-5 
yl)phenyl]phenyl]methyl]benzimidazole-4-
carboxylic acid
7 Molecular Formula C24H20N6O3
8 Chemical Structure
9 Molecular Weight 610.659660 [g/mol]
10 Melting Point 1630C
11 Solubility Sparingly soluble in methanol, insoluble in 
water
12 Predicted Water Solubility 7.71e-03 mg/Ml
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Pharmacological nature of Candesartan is given in table no.3
TABLE: 3 PHARMACOLOGICAL NATURE OF CANDESARTAN:
S.No
Pharmacological
Nature
Description
1 Indication For the treatment of hypertension and Heart Failure.
2 Mechanism of Action
Candesartan  competes  with  angiotensin  II  for  binding  at  the
AT1 receptor  subtype.  As angiotensin II  is  a  vasoconstrictor  which
also stimulates the synthesis and release of aldosterone, blockage of
its effects results in a decrease in systemic vascular resistance.
3 Drug Interactions
4
Phase 1 Metabolizing
Enzymes
Cytochrome P450 11B2 (CYP11B2)
5 Targets Type-1 angiotensin II receptor
6 BCS   Class II - Low Solubility and High Permeability
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Amiloride Increased risk of hyperkaliemia
Drospirenone Increased risk of hyperkaliemia
Lithium The ARB increases serum levels of lithium
Potassium Increased risk of hyperkaliemia
Spironolactone Increased risk of hyperkaliemia
Triamterene Increased risk of hyperkaliemia
Pharmacokinetic nature of Candesartan is given in Table no.4
TABLE: 4 PHARMACOKINETIC NATURE OF CANDESARTAN:
S.No Pharmacokinetic Nature Description
1
Absorption
Bioavailability is about 15%
2
Distribution
Vd is 0.13 L/kg
3
Metabolism
Candesartan cilexetil is bioactivated by ester hydrolysis 
during absorption from the GI tract to candesartan. 
Candesartan undergoes minor hepatic metabolism by O-
deethylation to an inactive metabolite.
4
Elimination
Primarily as unchanged drug in the urine and by the 
biliary route, in the feces. Plasma Cl is 0.37 mL/min/kg. 
Renal Cl is 0.19 mL/min/kg.
About 26% is excreted unchanged in urine.
5 T max 3 to 4 hrs
6 Half Life (t ½) Approximately 9 hrs
7 Protein binding More than 99%
8 Toxicity
No lethality was observed in acute toxicity studies in 
mice, rats and dogs given single oral doses of up to 2000 
mg/kg of candesartan cilexetil
       
Product Specifications of Candesartan are given in Table no.5
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TABLE: 5 PRODUCT SPECIFICATIONS OF CANDESARTAN 
S.No Product Specifications Description
1 Drug Type Approved
2 Dosage Form Tablet
3 Route of Administration Oral
4 Strength 4mg, 8mg, 16mg and 32mg
5 Non active Ingredients
Calcium CMC, maize starch, HPC, iron 
oxide lactose, magnesium stearate, PEG, 
Avicel.
6 Package Blister Pack
7 Storage Conditions Controlled room temperature
8 Available Brands Amias, Atacand, Blopress, Ratacand
EXCIPIENT PROFILE: 
MICROCRYSTALL  I    NE C E    LLU LO    SE 44  :
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Synonyms:  Avicel,  cellulose gel,  crystalline cellulose,  E460, Emocel,  Fibrocel,
Tabulose, Vivacel.
Functional Category: Tablet and Capsule diluent, suspending agent, adsorbent,
tablet disintegrant.
Applications: As a diluent in tablets (wet granulation and direct compression)
and  capsule  formulation.  In  addition  to  its  use  as  a  diluent,  it  also  has  some
lubricant and disintegrant property.
             Description: White-colored, odourless, tasteless crystalline powder composed of
porous particles. Available in different particle size grades which have different properties
and applications
          Solubility: Slightly soluble in 5 % w/v NaOH solution, practically insoluble in
water, dilute acids and most organic solvents.
Stability: It is a stable, though hygroscopic material.
Storage conditions: The bulk material should be stored in a well-closed container
in a cool, dry, place.
Incompatibilities: Incompatible with strong oxidizing agents.
Safety: It is generally regarded as a nontoxic and nonirritant material.
16
Commercial Grades of Microcrystalline Cellulose
Grade Nominal Mean Particle Size
Avicel PH 102 & 112.........................100 µm 
Avicel PH 101 & 103.........................50 µm 
Emocel 50 M......................................51 µm 
Vivacel 102 ........................................100 µm 
Vivacel 12 ..........................................180 µm
LACTOSE  45  :
Synonyms: Fast-Flo, Microlose, milk sugar, Pharmatose, Tablettose.
Functional Category: Tablet and Capsule diluent.
Applications:  As  filler  or  diluent  in  tablets  (wet  granulation  and  direct 
compression) and capsules, in lyophilized products and infant fed formulas.
Description: White to off-white crystalline particles or powder, odourless and 
slightly sweet-tasting.
Solubility: Freely soluble in water, practically insoluble in chloroform, ethanol 
and ether.
Stability: Under humid conditions (80 % RH and above) mold growth may occur.
Storage conditions: Lactose should be stored in a well-closed container in a cool, 
dry, place.
Incompatibilities: A Maillard-type condensation reaction is likely to occur between
lactose and compounds with a  primary amine group to form brown-  colored
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products.
Safety: Adverse reactions to lactose is largely attributed to lactose intolerance, 
which occurs in persons with a deficiency of the intestinal enzyme lactase
HYDROXY PROPYL CELLULOSE:
1. Nonproprietary Names
● BP: Hydroxypropylcellulose31
● JP: Hydroxypropylcellulose
● PhEur: Hydroxypropylcellulosum
● USPNF: Hydroxypropyl cellulose
2. Synonyms
Cellulose,  hydroxypropyl  ether;  E463;  hyprolose;  Klucel;  Methocel;  Nisso    HPC;
oxypropylated cellulose.
3. Chemical Name and CAS Registry Number
Cellulose, 2-hydroxypropyl ether [9004-64-2]
4. Empirical Formula and Molecular Weight
The PhEur 2005 and USPNF 23 describe hydroxypropyl cellulose as a partially substituted
poly(hydroxypropyl)  ether  of  cellulose.  It  may contain  not  more  than  0.6% of  silica  or
another suitable anticaking agent. Hydroxypropyl  cellulose is  commercially available in a
number of different  grades  that have various solution viscosities.  Molecular weight has a
range of 50 000–1 250 000; 
5. Structural Formula
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                          figure:8 : R is H or [CH2CH(CH3)O]mH
6. Functional Category
Coating  agent;  emulsifying  agent;  stabilizing  agent;  suspending  agent;  tablet  binder;
thickening agent; viscosity-increasing agent.
7. Applications in Pharmaceutical Formulation or Technology
Hydroxypropyl cellulose is widely used in oral and topical pharmaceutical formulations; 
In oral products, hydroxypropyl  cellulose is primarily used in tableting as a binder,1 film-
coating,2 and extended-release-matrix former.3–5 Concentrations of hydroxypropyl  cellulose
of 2–6% w/w may be used as a binder in either wet-granulation or dry, direct-compression
tableting processes.6–10 Concentrations of 15–35% w/w of hydroxypropyl cellulose may be
used to produce tablets with an extended drug release.11 The release rate of a drug increases
with decreasing viscosity of hydroxypropyl cellulose. The addition of an anionic surfactant
similarly increases the viscosity of hydroxypropyl cellulose and hence decreases the release
rate of a drug. Typically, a 5% w/w solution of hydroxypropyl cellulose may be used to film-
coat tablets. Aqueous solutions containing hydroxypropyl cellulose along with an amount of
methyl cellulose or ethanolic solutions have been used.12–14 Hydroxypropyl cellulose is also
used in microencapsulation processes and as a thickening agent. Hydroxypropyl cellulose is
also used in cosmetics and in food products as an emulsifier and stabilizer.
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8. Description
Hydroxypropyl cellulose is a white to slightly yellow-colored, odorless and tasteless powder.
Melting point:
Softens at 130°C; chars at 260–275°C.
MAGNESIUM STEARATE
1 Nonproprietary Names
BP: Magnesium stearate
JP: Magnesium stearate
PhEur: Magnesii stearas
USPNF: Magnesium stearate
2 Synonyms
Magnesium octadecanoate; octadecanoic acid, magnesium salt;
stearic acid, magnesium salt.
3Empirical Formula and Molecular Weight
C36H70MgO4 591.34
The USPNF 23 describes magnesium stearate as a compound
of magnesium with a mixture of solid organic acids that consists chiefly of variable 
proportions of magnesium stearate and magnesium palmitate (C32H62MgO4). The PhEur 
2005 describes magnesium stearate as a mixture of magnesium salts of different fatty acids 
consisting mainly of stearic acid and palmitic acid and in minor proportions other fatty acids
.
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4 Structural Formula
[CH3(CH2)16COO]2Mg
5 Functional Category
Tablet and capsule lubricant.
6 Description
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder of 
low bulk density, having a faint odor of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin.
7 Typical Properties
Crystalline forms: high-purity magnesium stearate has been
isolated as a trihydrate, a dihydrate, and an anhydrate.
Density (bulk): 0.159 g/cm³
Density (tapped): 0.286 g/cm³
Density (true): 1.092 g/cm³
Flash point: 250ºC
Flowability: poorly flowing, cohesive powder.
Melting range:
117–150ºC (commercial samples);
126–130ºC (high purity magnesium stearate).
Solubility: practically insoluble in ethanol, ethanol (95%), ether
and water; slightly soluble in warm benzene and warm
ethanol (95%)
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PG STARCH:
• Also called as starch derivative.
• Used as thickening agent,stabilizer or emulsifier.
• Soluble in cold water.
• Dryed by extrusion,drumdrying.
• Used to thicken instant desserts.
FERRIC OXIDE RED:
• Most common colorant in ceramics.
• It is very soft and fine powder.
• It is available from bright light red at a deep red marron. 
• In oxidation firing ion is an important source for tan.
CALCIUM CMC:  
• Molecular weight:201 m/w.
• It should be stable on storage.
• Grades like h,m,l are used.
• Used as emulsying agent,gelling agent,binding agent.
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2. AIM & OBJECTIVES:
Aim of the study:
Candesartan cilexetil is an angiotensin II inhibitor (ARB) drug that is sold under the brand
name “Atacand” in the United States by ASTRAZENECA. Patent expiration date for this
product  is  on  June  2012.  So,  the  aim  of  the  present  study  is  to  develop  and  evaluate
Candesartan  cilexetil  (generic  version)  with  respect  to  the  reference  sample  for  getting
marketing approval in United States. The formulation of tablets were done to match the in-
vitro drug release with respect to the reference drug and carry out the stability studies as per
the ICH guidelines.
Objectives:
Primary Objective:
1. To formulate and evaluate immediate release candesartan cilexetil tablets (32mg)
Secondary Objectives:
1. To perform preformulation studies including drug – excipient compatibility study.
2. To develop various formulations with different excipients.
3. To study the effect of excipient concentrations on the tablet characteristics.
4. To establish the invitro release compliance with the established criteria.
5. To achieve immediate release profile for the developed formulation.
6. To establish the stability of the formulation.
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3. PLAN OF WORK:
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4. MATERIALS AND METHODS:
The list of materials used for the formulation of Candesartan immediate release tablets 
are given in Table no. 6.
TABLE: 6 LIST OF MATERIALS USED IN THE FORMULATION
S.No Ingredients Specification Rationale Source
1. Candesartan Cilexetil USP API ArabindoPharmaceutical co.ltd
2. Lactose Monohydrate USP Diluent Avon organics Ltd
3. PG Starch USP Filler/Binder ArabindoPharmaceutical Ltd
4. Microcrystalline cellose(Avicel PH 101) USP Disintegrant SD Fine Chemicals ltd
5. Klucel – LF USP Binder SD Fine Chemicals ltd
6 Ca. CMC USP Superdisintegrants SD Fine Chemicals ltd
7 Mg. Stearate USP Glident SD Fine Chemicals ltd
8 Purified water USP Solvent NATCO Pharma Ltd
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The list of equipments used for the formulation of Candesartan immediate release tablets 
are given in Table no.7.
TABLE: 7 LIST OF EQUIPMENTS USED FOR THE FORMULATION 
Name of instrument Model no. Make
Electronic Weighing Balance PR 203 Mettler Toledo
Tap Density Tester USP ETD-1020 Electrolab
Electromagnetic  Sieve Shaker EMS-8 Electrolab
Electronic Moisture Analyzer HG 63 Mettler Toledo
Tablet Compression Machine-8 station MINI Press - II MT Rimek
Digital Hardness Tester TH 10503 Labindia
Disintegration Test Apparatus USP ED-2AL Electrolab
Friabilator USP EF-2 Electrolab
Mechanical Stirrer RQT-124D Remi Motors
Pharma R&D Coater Deluxe Ideal Cures
Fluid Bed Drier UT-150 Umang Pharmatech
Rapid mixture granulator RMG 25 Anchormark
Multi Mill MM 15 Anchormark
Weighing balance T-26I
Scaletec Instruments
(Citizen)
Tray Drier PPT TD6 Platinum Pharmatech
Dissolution  Test Apparatus Type II UV-Pharmaspec – 1700
DBK Instruments Ltd.,
Mumbai.
5. METHODS:
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4.1. PREFORMULATION STUDIES:
Preformulation  may  be  described  as  a  stage  of  development  during  which  the
physicochemical and biopharmaceutical properties of a drug substance are characterized. It is
an  important  part  of  the  drug  development  process.  The  information  relating  to  drug
development acquired during this phase is used for making critical decisions in subsequent
stages  of  development.  A  wide  variety  of  information  must  be  generated  to  develop
formulations  rationally.  Characterization  of  the  drug  is  a  very  important  step  at  the
preformulation phase of  product  development  followed by studying  the properties  of the
excipients and their compatibility.
The API was tested for the following properties:
• Organoleptic Properties
• Solubility
• Water Content
• Particle Size determination
• Flow Properties
 Angle of Repose
 Bulk Density
 Tapped Density
 Carr’s Index
 Hausner’s Ratio                                              
• Drug – Excipient compatibility study
4.1.1. Organoleptic Properties:
The drug sample was viewed visually and viewed under the compound microscope
for the determination of its color using the black and white backgrounds and nature of the
drug  sample.  Then  the results  were  compared  with  the  official  books and  United States
Pharmacopoeia.
4.1.2. Solubility:
The solubility of the drug sample was carried out in different solvents (aqueous and
organic) according to the United States Pharmacopoeia. The results are then compared with
those given in the official books and United States Pharmacopoeia.
4.1.3. Water Content:
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Transfer 35 to 40ml of a mixture of methanol to the titration vessel and titrate with
Karl  fisher  reagent  to  the electrometric  end point  to  consume any moisture  that  may be
present. Use powder from 5 tablets, grind to a fine powder in an atmosphere of temperature
and relative humidity known not to influence the results. Accurately weigh and transfer about
300-500mg of the powder in to the titration vessel, mix and titrate with the KF reagent to the
electrometric  endpoint.  Calculate  the  water  content  of  the  specimen in  mg taken  by the
formulae:
Calculation:
Where,
S = Volume in ml of reagent consumed in the second titration
F = Water equivalent factor of KF reagent
W = Weight of sample taken in mg
4.1.4. Flow Properties:
4.1.4.1. Angle of repose (θ):
It is a direct measure of flow property of powders. It is the maximum angle that can
be obtained between the free standing surface of a powder heap and the horizontal.
Procedure:
Angle of repose was determined using funnel to pour the powder on the surface from a fixed
height of 2cm. Circumference was drawn with a pencil on the graph paper and the radius of
base of a pile was measured at 5 different points and average was taken for calculating Angle
of repose using following formula:
Angle of Repose (Θ) = Tan-1 (H/R)
Where, 
 h = height of a pile (2 cm)
 r = radius of pile base.
Acceptance criteria for Angle of Repose is given in the Table no.8.
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Water (%) = S X F X 100
               W
TABLE: 8 ACCEPTANCE CRITERIA FOR ANGLE OF REPOSE
Range (0)                             Result
31 – 35Excellent
25 – 30 
Good
36 – 40 Fair
41 -  45 Passable
46 – 55 Poor
56 – 65 Very Poor
> 66 Very Very Poor
Acceptable range for angle of repose is 200 to 400. 
4.1.4.2. Bulk density:
It is the ratio of given mass of powder and its bulk volume determined by measuring
the volume of known mass of powder sample that has been passed through the screen in to
graduating cylinder.
Procedure:
Bulk density was determined according to USP method I. The powder sample under test was
screened through sieve no 18 and 10 mg of pure drug was accurately weighed and filled in a
100ml graduated cylinder and the powder was leveled and the unsettled volume (Vo) was
noted. Bulk density (Db) was calculated in g/ml by the formula:       
                                           
(Db)= M/Vo
Where, 
M = mass of powder taken
Vo= unsettled apparent volume
Limits:
It  has been stated that  the bulk density values  having less than 1.2 g/cm3  indicates  good
packing and values greater than 1.5 g/cm3 indicates poor packing. 
29
4.1.4.3   Tapped density:
Procedure:
Tapped density was determined by USP method II.  The powder sample under test
was screened through sieve no.18 and 10 mg of pure drug was filled in 100ml graduated
cylinder of tap density tester (electrolab, ETD 1020). The mechanical tapping of the cylinder
was carried out using tapped density tester at a normal rate of 250 drops per minute for 500
times initially and the initial tapped volume (Va) was noted. Tapping was proceeded further
for additional 750 times and volume was noted. The difference between two tapping volumes
was calculated. 
Tapping was continued for additional 1250 tap if the difference is more than 2%. This was
continued  in  increments  of  1250  taps  until  differences  between  volumes  of  subsequent
tapping was less than 2%. This volume was noted as, the final tapped volume (Vo).  The
tapped density (Dt) was calculated in g/ml by the formula:
Dt = M/ Vo
Where, 
M = weight of sample powder
Vo = final tapped volume
4.1.4.3. Compressibility Index and Hausner Ratio: 
Compressibility Index and Hausner Ratio are measures of the propensity of a powder
to  be  compressed.  As  such  they  are  measures  of  relative  importance  of  interparticulate
interactions. In free flowing powder, such interactions are less significant and bulk & tapped
density difference is close. For poorer flowing materials, this difference is greater.
a) Compressibility Index (% Compressibility):
Carr’s compressibility index i.e., % compressibility indicates the flow property and packing
ability of the tablet. It  is determined by measuring both the bulk and tapped density of a
powder. When the % compressibility ranges from 5 to 16, the materials have acceptable flow
property and packing ability. Compressibility Index was calculated using following equation:
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CI (%) = [(Dt -Db)/Dt] x100
Where,
 Dt = tapped density
 Db = bulk density
b) Hausner’s Ratio:
The  Hausner  ratio  indicates  the  flowability  and  packing  ability  of  the  tablet.  When  the
Hausner ratio is close to 1, materials have acceptable flow and packing ability. Hausner Ratio
was calculated using the formula:
Hausner Ratio = Dt/Db
Where,
 Dt = tapped density
 Db = bulk density
Acceptance criteria of flow properties are given in the Table no.9.
TABLE: 9 ACCEPTANCE CRITERIA OF FLOW PROPERTIES
Compressibility Index Flow Character Hausner Ratio
1 – 10 Excellent 1.00 – 1.11
11 – 15 Good 1.12 – 1.18
16 – 20 Fair 1.19 – 1.25
21 – 25 Passable 1.26 – 1.34
26 – 31 Poor 1.35 – 1.45
32 – 37 Very Poor 1.46 – 1.59
> 38 Very Very Poor > 1.60
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4.1.5. Drug – Excipient Compatibility Study:
Drug is in intimate contact with one or more excipient in all the dosage forms. Later it
could  affect  the  stability  of  drug.Knowledge  of  drug  excipient  interaction  is  useful  in
selecting an appropriate excipient. 
Procedure:
API and excipient are taken in the ratios above mentioned and mixed together in a polybag
for 5 min. Each mixture is allotted sample code for identification.  4 sets of sample were
allocated where each sample mixture is divided in to 1g in to its corresponding glass vial
(USP Type I) at different conditions. 
All  vials  are  properly  sealed  and loaded at  respective  conditions.  The samples  are  to be
checked for its Description, Related substance and water content by KF.
Drug – Excipient ratio for compatibility study details are given in Table no.10.   
TABLE: 10 DRUG – EXCIPIENT RATIO FOR COMPATIBILITY STUDIES:
S.No Drug – Excipient Ratio
1 Candesartan + Corn starc0h 1:5
2 Candesartan + PEG 6000 1:5
3 Candesartan + Calcium CMC 1:5
4 Candesartan + Klucel EF 1:5
5 Candesartan + Klucel LF 1:5
6 Candesartan + Ferric oxide red 1:0.1
7 Candesartan + Magnesium stearate 1:1
8 Candesartan + Avicel 1:5
9 Candesartan + Lactose 1:5
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4.1.5.1. Sampling schedule:
The prepared  drug  and excipient  mixtures  were  evaluated  at  various  intervals  for
related substances  by HPLC as  per  the following conditions and time intervals.Sampling
schedule for compatibility study is given in Table no.11.  
TABLE: 11 SAMPLING SCHEDULE:
S.No Condition Duration No. of Sets
1 Initial 0 days 1
2 550C ± 20C 14 days 1
3 40 ± 20C & 75 ± 5% RH 14 days 1
4 40 ± 20C & 75 ± 5% RH 28 days 1
4.1.5.2. Tests to be performed: 
S.No Parameters
Conditions
Initial 550C ± 20C 40 ± 20C & 75 ± 5% RH
0 Day 14th Day 14th Day 28th Day
1 Physical Appearance    
2 Related Substance    
4.2. FORMULATION OF CANDESARTAN IR (32MG) TABLETS:
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4.2.1. Formulation Planning:
The immediate release tablets containing 32mg Candesartan Cilexetil were prepared with a
total tablet weight of 260mg. Based on the results of preformulation studies; to improve the
flow properties tablets were prepared by Wet Granulation Technique and the composition are
given  in  Table  1.  Based  on  Literature  survey  and  Compatibility  Tests  excipients  like
Microcrystalline Cellulose (pH 101), PEG – 6000, PGS, Hydroxypropyl cellulose, Carboxy
Methyl Cellulose, Magnesium stearate were used.
4.2.2. Manufacturing Procedure:
• Weighed candesartan, Lactose and PG starch was passed through 40 mesh and then 
mixed. 
• Weighed PEG 6000 is transferred into 50ml of purified water and then stirred by using 
mechanical stirrer to get clear solution.
• Weighed klucel poured in to above PEG solution and then stirred to get turbid solution by
using mechanical stirrer.
• Above blend is made into dough mass by using this binder solution.
• This dough mass is passed through 14 mesh to get wet granules.
• These are dried by using FBD at 60oc.
• Dried granules were passed through 18 mesh.
• Weighed Cal.CMC passed through 40 mesh and then added to above granules and then 
mixed.
• Weighed Mg.Stearate is passed through 40 mesh and then added to above blend and then 
mixed.
• Then compressed and punched.
4.3. EVALUATION OF FORMULATION:
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4.3.1. Evaluation of granules:
4.3.1.1. Flow Properties:
The flow properties of the granules were evaluated as per the method described in the section
4.1.4.
4.3.1.2. Micromeretic properties:
The bulk density and tapped density of the granules were evaluated as per the method described
in the section 4.1.4.3. 
4.3.2. Evaluation of tablets:
4.3.2.1. Weight variation:
Weight variation was calculated as per method descried in USP. Twenty tablets were selected
at random and their average weight was determined using an electronic balance. The tablets
were weighed individually and compared with average weight.The requirements are met if
the weights of not more than 2 of tablets differ by more than the percentage listed in the
Table 12 and no tablets differ in weight by more than double that percentage.
                         Table: 12 Acceptance Criteria for Weight variation of Tablets
Average weight of tablet (mg) Percentage difference allowed
≤130 10
130-324 7.5
>324 5
4.3.2.2. Tablet thickness:
Thickness and diameter of formulation trials were measured using a Digital Hardness Tester.
Ten  tablets  of  each  trial  formulation  were  taken  and  measured  individually  at  frequent
intervals.
4.3.2.3. Hardness:
Ten tablets from each batch were selected and hardness was measured using Digital hardness tester to
find the average tablet hardness or crushing strength.
4.3.2.4. Friability (%):
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Friability was determined by taking 20 tablets. Tablets samples were weighed accurately and placed
in friabilator after the given specification (4 min at 25 rpm). The tablets were weighed again and %
friability was then calculated by:
%F = {(W – W0)/W} x 100
     Where, 
% F = Friability of tablets in percent.
 W = Initial Wight of tablets.
WO = Final weight of tablets.
4.3.2.5. Disintegration Test:
Disintegration  test,  measured  using  USP  tablet  disintegration  test  apparatus  (ED2L,
Electrolab, India) using 900 ml of distilled water at room temperature (37±20C).
4.3.2.6. In-vitro Dissolution Release study:
4.3.2.6.1. Dissolution conditions:
Medium : 0.7% tween-20 in 0.05 M phosphate buffer, PH 6.5
Volume : 900ml
Temperature : 37oC ± 0.5oC
Apparatus : USP type –II (paddle)
RPM : 50
Time interval : 10, 20, 30, 45 and 60 min
4.3.2.6.2. Chromatographic conditions:
Column : Hypersill BDS-C8 (150 X 4.6mm) 5µm
Flow rate : 1.5ml/min
Wave length : UV-210nm
Injection volume : 10µL
Column temperature : 40 oC
Run time : 10min
4.3.2.6.3. Buffer Preparation:
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Mix  1ml  of  orthophophoric  acid  in  1000ml  of  purified  water.  Filter  the  solution
through 0.45µ membrane. Filter and degas.
4.3.2.6.4. Mobile phase preparation:
Prepare a filtered and degas mixture of buffer and acetonitrile in the ratio of 40:60 v/v
respectively.
4.3.2.6.5. Standard preparation:  
Accurately  weigh  and  transfer  about  35.5mg  of  candesartan  cilexetil  working
standard in to a 200ml volumetric flask. Add about 20ml of acetonitrile, sonicate to
dissolve. Cool the solution to room temperature and dilute to volume with dissolution
medium. Transfer 5ml of standard stock preparation into a 25ml volumetric flask and
dilute  to  volume  with  dissolution  medium  (0.05  M  phosphate  buffer,  pH  6.5
containing 0.7% tween-20).
4.3.2.6.6. Sample preparation:
Place one tablet  in each  of  six  dissolution flasks  containing 900ml of  dissolution
medium previously maintained at 37oC ± 0.5oC taking care to exclude air bubbles
from the surface of each dosage unit and immediately operate the apparatus specified
time intervals.
After completion of each specified time interval withdraw a portion of solution from
zone midway between the surface of the dissolution medium and top of the rotating
blade, not less than 1cm from vessel wall ad filter through 0.45µ membrane filter.
4.3.2.6.7. Procedure:
Separately inject equal volume (10 µL) of dissolution medium as blank, standard and
sample  preparations  in  to  the  chromatograph  and  record  the  chromatograms  and
measure  the  peak  area  responses  for  the  analyte  peak  and  calculate  the  %  drug
dissolved of candesartan in the portion of candesartan tablets taken by the formula:
4.3.2.6.8. Calculation:
% of labeled amount of candesartan dissolved:
Where,
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TA    X    SW    X      5      X     900      X      P     X     100
SA           200           25      1              100             32
SA = Peak area response due of candesartan from standard preparation
TA = Peak area response due of candesartan from sample preparation
SW = Weight of candesartan working standard (mg)
P = Purity of candesartan working standard
4.3.2.7. Assay (HPLC):
4.3.2.7.1. Chromatographic conditions:
Column : Hypersill BDS-C8 (150 X 4.6mm) 5µm
Flow rate : 1.5ml/min
Wave length : UV-210nm
Injection volume : 10µL
Column temperature : 40 oC
Run time : 25min
4.3.2.7.2. Preparations:
• Mobile Phase – A:
Mix  1ml  of  orthophophoric  acid  in  1000ml  of  purified  water.  Filter  the  solution
through 0.45µ membrane. Filter and degas.
• Mobile Phase – B:
Acetonitrile – HPLC grade, Filter the solution through 0.45µ membrane filter.
• Diluent Preparation:
Prepare a degassed mixture of mobile phase A and acetonitrile in the ratio of 30:70
v/v respectively.
• Standard preparation:
Accurately  weigh  and  transfer  about 32mg of  candesartan  working standard in to
100ml volumetric, add 60ml of diluent and sonicate to dissolve. Cool the solution to
room temperature  and  dilute  to  volume  with  diluent.  Transfer  5ml  of  the  above
solution in to a 50ml volumetric flask and dilute to volume with diluent.
  
• Sample preparation:
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Accurately weigh and transfer 5 tablets in to a 100ml volumetric flask. Add about
60ml of diluent and sonicate for 30min with occasional shakings. Cool the solution to
room temperature  and  dilute  to  volume with  diluent  and  mix.  Filter  the  solution
through 0.45µ membrane filter.
Transfer 2ml of the above filtered solution in to a 100ml volumetric flask and dilute
to volume with diluent.
4.3.2.7.3. Procedure:
Separately inject equal volume of diluent as blank, standard and sample preparations
in to the chromatograph and record the chromatograms and measure the peak area
responses  for  the analyte  peak  and  calculate  the % content  of  candesartan  in  the
portion of candesartan tablet taken by formula:
4.3.2.7.4. Calculation:
% of content of candesartan cilexetil:
Where,
SA = Peak area response due of candesartan from standard preparation
TA = Peak area response due of candesartan from sample preparation
SW = Weight of candesartan working standard (mg)
P = Purity of candesartan working standard
TW = Weight of sample
LA = Label amount
5. RESULTS AND DISCUSSIONS:
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TA    X    SW    X      5      X     100      X     100     X      P    X    Avg Wt     X    100
SA           100           50    TW               2              100 LA
5.1. Preformulation studies:
Preformulation  studies  like Physical  Characterization,  Solubility,  Moisture  Content,  Flow
properties  like  Angle  of  Repose,  Bulk  Density,  Tapped  Density,  Compressibility  Index,
Hausner ratio and Compatibility studies were performed and the obtained data are presented
in the Table no.13,14,15. 
5.1.1. Physical Characterization of API:
TABLE: 13 RESULTS OF PHYSICAL CHARACTERIZATION OF THE DRUG
S.No: Description Result
1. Appearance White to off-white powder
2. Odour Characteristic odour.
3. Solubility
Freely soluble in Methylene chloride. Slightly 
soluble in methanol, Practically insoluble in 
water.
4. Water Content 0.07 %
The above result shows that physical characterization of the drug candidate (API) complies 
with the USP specifications.
5.1.2. Flow Properties:
TABLE: 14 RESULTS OF FLOW PROPERTIES
S.No Flow Properties Result
1 Bulk density (g/ml) 0.581
2 Tapped density (g/ml) 0.714
3 Carr’s index (%) 18.62
4 Hausner’s ratio 1.22
5 Angle of repose 22o.8l
From the above results, it is found that the API has “fair” flow properties.
5.1.3. Compatibility studies results:
TABLE: 15 COMPATIBILITY STUDIES RESULTS
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Excipients % known impurities % Unknown impurities Total impurities
I II III I II III I II III
Lactose 0.15 0.2 0.3 0.01 0.02 0.04 0.4 0.6 0.8
PEG 6000 0.1 0.15 0.4 0.04 0.05 0.08 0.2 0.4 0.7
PG Starch 0.1 0.12 0.3 0.02 0.05 0.09 0.1 0.3 0.5
HPC 0.2 0.25 0.35 0.02 0.04 0.08 0.2 0.3 0.6
Ca CMC 0.2 0.18 0.28 0.01 0.04 0.05 0.3 0.5 0.9
Mg.Stearate 0.1 0.15 0.18 0.03 0.04 0.05 0.2 0.3 0.5
I = INITIAL 
II = LONG TERM (28 DAYS)
III = ACCELERATED (14 DAYS)
No Characteristic change in the color of the powder and no additional degradation of the
product was observed. The increase in impurities at the end of the accelerated condition is
not significant. All the excipients are stable and compatible with active ingredient. Hence, it
is recommended that the above excipients can be used in further formulation development
trials.
Analytical Evaluation:
Standard Chromatograms:
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Blank Chromatogram:
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FORMULATION TRIALS:
The Immediate Release tablets of Candesartan 32mg has been formulated as described in the 
section 4.2 and the formula is shown in the table 16
Ingredients F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10
Candesartan 32 32 32 32 32 32 32 32 32 32
Lactose
Mono
Hydrate
155.98 155.98 164.97 164.97 166.97 162.5 162.5 52 - 164.97
PEG 6000 12 12 6 2 - 6 6 12 - 6
Lycatab PGS/
Corn starch 40 40 40 40 40 40 40 25 25 40
Ferric oxide
Red 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Klucel LF 8 8 8 12 12 10 10 12 12 8
Avicel - - - - - - - 100 150 -
Purified
Water 70 70 70 70 70 60 70 70 120 70
Ca CMC 11.2 11.2 8 2 8 8 8 25 25 8
Mg.stearate 0.8 0.8 1.0 1 1 1.5 1.5 2 2 1.0
Total (mg) 260 260 260 260 260 260 260 260 260 260
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F – 1 & 2: Formulate candesartan cilexetil (32mg) by using  unmicronized and micronized
API.
Objective:  These Trials are  done to determine whether particle size vary with dissolution
rate and flow properties or not
Inference: Micronized API (F – 2) showed good flow properties with required Dissolution.
F – 3: Formulate candesartan cilexetil by reducing PEG and ca CMC concentration.
Objective: These Trials are done to match the Innovator in terms of Appearance, Thickness,
Hardness and to achieve 80% drug release within 10 min.
Inference: Did not achieve required Hardness and Drug release
F – 4: Formulate candesartan cilexetil by reducing PEG and Increasing Klucel.
Inference: Did not achieve required drug content.
F – 5: Formulate candesartan cilexetil without PEG.
Inference: 
a) Achieved required Hardness 
b) Did not achieve required Drug release
F – 6 & 7: Formulate candesartan cilexetil by changing the water quantity
Objective: These Trials are done to determine the effect of the water quantity 
Inference: 
a) F – 6 (60ml): Decrease in Hardness
b) F – 7 (70ml): Increase in Hardness
F – 8: Formulate candesartan cilexetil by incorporating Avicel PH 101 and reducing Lactose,
Starch.
Objective: These Trials are done to determine the effect of Avicel PH 101 on the hardness
and drug release 
Inference: Achieved required Drug release
F –  9:  Formulate  candesartan  cilexetil  by  incorporating  Avicel  PH 101  and  eliminating
Lactose, PEG.
Inference: Achieved required Hardness and Drug release
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F – 10: Formulate candesartan cilexetil using Direct Compression.
Objective:  The  objective  of  this  trial  is  to  formulate  candesartan  cilexetil  using  direct
compression technique 
Inference: Resulted in Poor Flow properties. 
From the above trials F -8 is considered the best formulation
RESULTS OF FLOW PROPERTIES OF LUBRICATED BLEND:
The evaluation results for flow properties of granules are described in the following table 
17.
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Table No: 17 Evaluation of Granules:
S.No Formulations
Bulk
Density
(g/ml)
Tapped
Density
(g/ml)
Compressibility
Index (%)
Hausner’s
Ratio
1 F-1 0.596 0.785 24.07 1.31
2 F-2 0.581 0.714 18.60 1.22
3 F-3 0.654 0.802 18.45 1.22
4 F-4 0.694 0.834 16.67 1.2
5 F-5 0.480 0.625 23.07 1.30
6 F-6 0.694 0.833 16.66 1.2
7 F-7 0.625 0.781 20.00 1.25
8 F-8 0.609 0.781 21.95 1.28
9 F-9 0.510 0.641 20.40 1.25
10 F-10 0.500 0.735 32 1.470
Inference: 
A. F – 1, F – 5, F – 8 showed “Passable” flow properties
B. F-2, F-3, F-4, F-6, F-7, F-9 showed “Fair” flow properties
C. F – 10 showed very poor flow properties
RESULTS OF EVALUATION OF TABLETS:
The evaluation results of in process properties of tablets are described in the following 
table 18.
Table No: 18 Evaluation of Tablets:
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S.No Formulations Thickness(mm)
Hardness
(kg/cm2)
Disintegration
(Min)
Friability
(%)
1 F-1 3.62 ± 0.0097 4.1 ± 0.031 3.16 0.153
2 F-2 3.62 ± 0.0166 5.1 ± 0.032 3.02 0.106
3 F-3 3.46 ± 0.0353 6.19 ± 0.22 8.5 0.377
4 F-4 3.46 ± 0.0244 9.75 ± 0.514 14.55 0.24
5 F-5 3.48 ± 0.0294 10.44 ± 0.492 11.5 0.17
6 F-6 3.47 ± 0.0531 7.1 ± 0.278 12 0.28
7 F-7 3.47 ± 0.0526 9.45 ± 0.59 12 0.23
8 F-8 3.53 ± 0.0222 8.12 ± 0.472 11 0.06
9 F-9 3.55 ± 0.0194 9.6 ± 0.354 5.5 0.06
10 F-10 3.55 ± 0.0163 7.1 ± 0.278 2 0.167
11 Innovator 3.50 ± 0.049 9.8 ± 0.14 11.17 0.15
IN-VITRO DISSOLUTION RELEASE:
Comparative In-vitro  Dissolution release profile for Reference and all formulations at  60
Minutes is given in the table 19
 
Table No: 19  % of Drug Release (Candesartan Cilexetil):
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S.No Time F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 Innovator
1 10 67.6 86.4 68.9 31.6 56.5 41.4 38.4 56.9 84.7 80 40.9
2 20 72.4 95.8 96 61.8 86.5 79.9 74.5 95 94.7 87.8 73.7
3 30 77.9 103.8 97.6 84.0 96.2 94.9 97.0 101.3 99.9 91.2 89.6
4 45 84.6 104.5 97.9 94.9 96.4 100.1 104.3 103.6 104.6 93.4 96.2
5 60 92.5 106.5 98.6 98.3 97.1 102.6 106.5 104.4 107.0 94.7 98.6
49
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Based on these parameters we have optimized F – 08 as the best formulation and decided as 
the final formula.
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Stability Data of Trial F – 08:
Dissolution of trial F – 08 tablets were comparable with reference product. So tablets of this
batch were kept for stability studies.
              After 3 months the physical parameters of the tablets were same. Water content and
related substance are with in limits. Tablets were passing the stability studies. The tablets
were tested for average weight, thickness, hardness, friability, Disintegration, water content
and RS at initial, 1 month and 3 months.
Table No:20 Stability Study data of Trial F – 08:
S.No Parameters
Conditions
Initial 250C ± 20C 40 ± 20C & 75 ± 5% RH
0 Day 3 Months 1 Month 3 Month
1 Average Weight 260.2 + 0.13 260.2 + 0.13 260.2 + 0.13 260.2 + 0.13
2 Thickness 3.53 ± 0.02 3.51 ± 0.04 3.52 ± 0.06 3.48 ± 0.02
3 Hardness 8.12 ± 0.47 7.8 ± 0.24 8.1 ± 0.36 7.7 ± 0.45
4 Friability 0.06 0.3 0.17 0.21
5 Disintegration 11 10 11 9
6 Assay 99.8 101.9 97.7 94.3
7 Water Content (%) 4.6 3.8 4.2 4.5
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SUMMARY
The study was undertaken with an aim to formulate and evaluate conventional candesartan
cilexetil(32mg) (generic version) with respect to the reference sample for getting marketing
approval in United States.
API characterization was performed in aspects of colour, form ,taste, melting point, solubility
.Preformulation  studies  were  carried  and  the  results  were  found  to  be  satisfactory.
Experimental started with the  Process variables such as Bulk density, Tapped density,Angle
of repose,Compressibility index of API.Drug excepient compatibility test were performed
and the compatible excepients were selected for Formulation development.
Conventional tablets of candesartan cilexetil  were prepared by wet granulation technique.
The formulated tablets were evaluated for Drug content,Hardness, Friability,Disintegration
time, Dissolution rate characteristics.The results were compared with Innovator product.
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CONCLUSION
•Candesartan cilexetil is white to off white crystalline powder,Bitter to taste
•  Candesartan cilexetil is freely soluble in solvents like Methylene chloride,6.5 Ph buffer ,
slightly soluble in Methanol, practically insoluble in Water.
•The compatibility study results Explain that there is no characteristic change in the colour of
the  powder  and  no  additional  degradation  of  the product  was  observed.  The  increase  in
impurities at the end of the Accelerated condition is not significant.All the excepients are
stable  and  compatible  with  active  ingredient.Hence,it  is  recommended  that  the  above
Excepients can be used in further formulation development trials.
• Conventional tablets of candesartan celexitil  were prepared by Wet granulation Technique.
All the tablets prepared  fulfilled the Official USP Requirements of Drug content , Hardness,
Friability and Disintegration time.
•The Dissolution of the drug followed 1 order kinetics in all formulations.
•F1 and F2 showed good flow properties with required Dissolution.
•F3 did not achieve required hardness and drug release.
•F4 did not achieve required drug content.
•F5 has adequate hardness and doesn’t achieve Drug release.
•F6 and F7 decrease in hardness and increase in hardness.
•F9and F10 resulted in poor flow properties.
•F8  showed  higher  dissolution  when  compared  to  the  other  formulations  and  Innovator
product.
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Hence the increase in Dissolution of F8 may be due to the presence of PEG-6000, LACTOSE
MONOHYDRATE AND AVICEL pH   102.
Stability studies were performed for this batch for 1 and 3 months under Accelerated and
long  term  conditions.Finally  after  the  duration,  the  product  was  analyzed  for  physical
appearance, Hardness,Thickness, Friability,Loss on drying, disintegration, Assay and Related
substance. The results obtained were found to be with in the specified limits.
The bigger scale confirmatory batch is under 6 months Accelerated stability condition, based
on the result, a pilot scale will be executed.
After  passing  the  above  tests,  the  in-vivo  studies  (BA/BE  Studies)  will  be  executed  to
correlated the bioequivalence of best formulation (Trial F – 08) with the reference drug.
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